NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1095 coverSignal Transduction Pathways, Part C: Cell Signaling in Health and Disease Volume 1095 published December 2006
Ann. N.Y. Acad. Sci. 1095: 26–34 (2007). doi: 10.1196/annals.1397.004
Copyright © 2007 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by SONG, Y.-C.
Articles by SONG, Y.-S.
Search for Related Content
PubMed
PubMed Citation
Articles by SONG, Y.-C.
Articles by SONG, Y.-S.

Part I. Cancer

Apoptotic Effect of Celecoxib Dependent Upon p53 Status in Human Ovarian Cancer Cells

YOO-CHEOL SONGa, SU-HYEONG KIMa, YONG-SUNG JUHNNa,b AND YONG-SANG SONGa,c

a Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea b Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 110-744, Korea c Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 110-744, Korea

Key Words: ovarian cancer • NSAIDs • celecoxib • p53 • caspase • apoptosis

Address for correspondence: Yong-Sang Song, M.D., Ph.D., Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 28 Yongun-dong, Chongno-gu, Seoul, 110-744, Korea. Voice: 82-2-2072-2822; fax: 82-2-3668-7401.  e-mail: yssong{at}snu.ac.kr

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, induces the apoptosis in various cancers in COX-2 dependent and/or independent manners. The p53 protein is mutated in 50% of all human tumors and plays a key role in apoptosis, cell cycle, and the expression of several proteins. In ovarian cancer, the rate of p53 mutation has been shown to be very high and associated with poor prognosis. To explore the importance of functional status of p53 in apoptosis by celecoxib in ovarian cancer cells, the cellular response to celecoxib was determined in SK-OV3 ovarian cancer cells with null type p53 and PA-1 with wild-type p53. Our results showed that celecoxib inhibited cell growth more in PA-1 than in SK-OV3. The underlying antiproliferative mechanism may differ between these two cell types dependent upon the functional status of p53, which plays integral roles in regulating cell cycle and survival. Higher sub-G1 was shown in PA-1 than in SK-OV3 in response to celecoxib (PA-1 versus SK-OV3; 60.28% versus 6.69%). Caspase -8, -9, and -3 were activated in PA-1 cells, but not in SK-OV3 cells. These results suggest that death receptor and mitochondria-mediated apoptotic pathways may be involved in celecoxib-induced apoptosis dependent upon the functional status of p53. Our article demonstrated that the celecoxib effectively inhibited cell growth and induced apoptosis in human ovarian cancer cells with wild-type p53. Thus, apoptotic effect by celecoxib seemed to be different dependent upon the functional status of p53.






footerLeft footerRight